• Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
Wednesday, November 18, 2026
No Result
View All Result
Subscribe Now
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
The Insight Post
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
No Result
View All Result
No Result
View All Result
Home Asia

Is Paxlovid too expensive for China to purchase? — Radio Free Asia

by Theinsightpost
January 14, 2023
in Asia
0 0
0
Is Paxlovid too expensive for China to purchase? — Radio Free Asia


In Brief

China’s National Healthcare Security Administration recently broke off talks with Pfizer to include Paxlovid among the medications eligible for reimbursement under the country’s national health insurance system. Officials said the company was charging too much for the antiviral medicine. 

Many netizens on popular Chinese social media sites WeChat and Weibo have further blamed the joint World Health Organization (WHO) and the Medicines Patent Pool for not including China amongst the upper-middle income countries eligible to receive generic COVID medications at cheap prices.

Asia Fact Check Lab (AFCL) found it misleading to blame the breakdown of talks on Pfizer’s pricing for Paxlovid. China’s own per-capita income statistics preclude it from buying Paxlovid at the same price as other upper-middle income countries, and the vast sums the country has spent on combating COVID – both inside and outside its borders – indicate that the price of a single medication is not likely a critical issue. 

In Depth

China’s healthcare security agency on Jan. 8 announced that Paxlovid, an oral medication “strongly recommended” by WHO in use against COVID, would not be added to the list of medications eligible for reimbursement under domestic healthcare plans due to its cost. 

The decision was made in spite of findings from China’s National Health Commission that detail the drug’s usefulness in treating patients in the early and intermediate stages of infection. Skyrocketing demand for the medicine has made it almost impossible to legally obtain in China, and black market scalpers regularly fetch tens of thousands of yuan for a box.

Is Pfizer asking too high a price for Paxlovid?

Details of China’s negotiations with Pfizer were not publicly released. An article published by Chinese media conglomerate Tencent cited an insider source as saying that an offer to sell Paxlovid for 700 yuan ($104) per course was rejected. Neither side has confirmed the statement.

Pfizer CEO Albert Bourla mentioned the negotiations at the J.P. Morgan Healthcare Conference held on Jan. 9. He noted that Paxlovid prices are based on the income levels where it is sold. “They (China) want it lower than the lowest of the middle, and we didn’t agree,” Bourla said. “They are the second highest economy in the world, and I don’t think that they should pay less than El Salvador.”

Paxlovid received emergency approval from the State Food and Drug Administration on Feb. 11, 2022, with the first batch of 21,200 boxes selling for 2,300 yuan per course the following month. One course includes 30 tablets meant to be consumed over five days.

Before the latest round of negotiations began, the People’s Daily, a government-aligned newspaper, reported that the price for a course of Paxlovid under a government healthcare plan had dropped from 2,300 yuan to 1,890 yuan. If patients were able to obtain maximum reimbursement, their out-of-pocket payment would only be 189 yuan per course. 

Some countries have purchased Paxlovid directly with national funds to minimize the costs for patients. The U.S. has ordered 10 million doses priced at around $530 (3,700 yuan) per course, offered free to eligible patients who test positive for COVID. The German Federal Ministry of Health purchased 1 million doses at a cost of 500 euros per course (3,640 yuan). The governments of Taiwan and Hong Kong bought Paxlovid for about $700 (4,716 yuan) per course.

All these prices are at least a thousand yuan higher than prices in China.

Is China a low or middle-income country?

Several WeChat and Weibo users have claimed that buying Paxlovid without the discounts provided by a licensing agreement signed between Pfizer and the Medicines Patent Pool (MPP) – an international public health agency that works with pharmaceutical companies to provide critical medications poorer countries at low costs to — would place undue financial stress on China’s healthcare system.

The agreement allows generic knockoffs of Paxlovid to be sold royalty-free in low, lower-middle and some upper-middle income countries. According to self-reported World Bank data, China has been listed amongst upper-middle income countries since 2010 and its current GDP per capita of $12,234 places the country near the top of upper-middle income countries. The MPP uses the same data to determine countries’ eligibility to buy their generic Paxlovid. 

And the country appears to have plenty of money on hand. The National Healthcare Security Admission split a bill of over 120 billion yuan ($17 billion) on vaccines with China’s Ministry of Finance since COVID broke out, and still retained a surplus of more than 500 billion yuan ($74 billion) in 2022 alone, according to National Health Insurance Administration data. China has donated an additional $200 million to several international COVID response funds.

China promotes domestically produced medicines

In denying coverage for Paxlovid, China may be opening up market space for local drug companies. 

On Jan. 6, the National Health Insurance Administration issued its Guidelines for Setting COVID Drug Treatment Prices (Trial Implementation). Hu Shanlian, a professor at Fudan University’s School of Public Health, told the People’s Daily that the guidelines will ensure the affordability of COVID medicines produced in China. “Ordinary people will be able to buy these drugs at low cost,” he said. “Domestically produced COVID medication will thus gain a larger market share than imports, due to their cost advantage and effective treatment.”

Just as negotiations with Pfizer broke off, two Chinese-made medications – Azvudine tablets and Qingfei Paidu granules – were cleared to be included as reimbursable COVID medications under national health insurance plans. Azvudine was originally a medication for HIV patients, only approved as a treatment for COVID in July 2022. Qingfei Paidu is a traditional Chinese medicine that lacks data from phase 3 clinical trials that show whether the medication might cause less common side effects in specific groups of people.

Asia Fact Check Lab (AFCL) is a new branch of RFA, established to counter disinformation in today’s complex media environment. Our journalists publish both daily and special reports that aim to sharpen and deepen our readers’ understanding of public issues.





Source link

ShareTweetSend
Previous Post

Exeter leave Loftus feeling battered & bruised, but also mugged

Next Post

#MeToo Puritans Remove Cleavage from Elvira Doll

Related News

Chinese Automakers Take the Lead in Myanmar’s EV Market, Surpassing Japanese Competitors
Asia

Chinese Automakers Take the Lead in Myanmar’s EV Market, Surpassing Japanese Competitors

November 18, 2026
Sarawak: Navigating the Unfulfilled Vision for Progress and Development
Asia

Sarawak: Navigating the Unfulfilled Vision for Progress and Development

November 18, 2026
Bentley Shifts Gears: Unveils Lightning-Fast Electric Revolution
Asia

Bentley Shifts Gears: Unveils Lightning-Fast Electric Revolution

November 15, 2026
سرکاری اسکولوں میں 73.4 فیصد کلاسز ریاستی قانون کی اخلاقیات پر پورا اترتی ہیں: VOSA رپورٹ
Asia

سرکاری اسکولوں میں 73.4 فیصد کلاسز ریاستی قانون کی اخلاقیات پر پورا اترتی ہیں: VOSA رپورٹ

November 14, 2026
Next Post
#MeToo Puritans Remove Cleavage from Elvira Doll

#MeToo Puritans Remove Cleavage from Elvira Doll

Discussion about this post

Subscribe To Our Newsletters

    Customer Support


    1251 Wilcrest Drive
    Houston, Texas
    77042 USA
    Call-832.795.1420
    e-mail – news@theinsightpost.com

    Subscribe To Our Newsletters

      Categories

      • Africa
      • Africa-East
      • African Sports
      • American Sports
      • Arts
      • Asia
      • Australia
      • Business
      • Business Asia
      • Business- Africa
      • Canada
      • Defense
      • Education
      • Egypt
      • Energy
      • Entertainment
      • Europe
      • European Soccer
      • Finance
      • Germany
      • Ghana
      • Health
      • Insight
      • International
      • Investing
      • Japan
      • Latest Headlines
      • Life & Living
      • Markets
      • Mobile
      • Movies
      • New Zealand
      • Nigeria
      • Politics
      • Scholarships
      • Science
      • South Africa
      • South America
      • Sports
      • Tech
      • Travel
      • Travel-Africa
      • UK
      • USA
      • Weather
      • World
      No Result
      View All Result

      Recent News

      The Critical Role of ADCCE in Shaping Today’s Global Landscape

      The Critical Role of ADCCE in Shaping Today’s Global Landscape

      November 18, 2026
      La La Anthony and Ciara Show Their Support for Kiyan Anthony at Madison Square Garden

      La La Anthony and Ciara Show Their Support for Kiyan Anthony at Madison Square Garden

      November 18, 2026
      Transforming American Global Health Aid: A New Era Begins

      Transforming American Global Health Aid: A New Era Begins

      November 18, 2026
      Elon Musk Scores Big with Witty Retort to Democratic Allegations of Wrongdoing

      Elon Musk Scores Big with Witty Retort to Democratic Allegations of Wrongdoing

      November 18, 2026
      • Home
      • Advertise With Us
      • About Us
      • Corporate
      • Consumer Rewards
      • Forum
      • Privacy Policy
      • Social Trends

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      Welcome Back!

      Login to your account below

      Forgotten Password?

      Retrieve your password

      Please enter your username or email address to reset your password.

      Log In

      Add New Playlist

      We are using cookies to give you the best experience on our website.

      You can find out more about which cookies we are using or switch them off in .

      No Result
      View All Result
      • Home
      • Insight
      • Blog
      • Business
      • Entertainment
      • Health
      • Politics
      • Shop
        • Gift Shop
        • Value Shop
        • Store
        • Bargain Shop
        • Discount
      • Sports
      • Tech
      • Travel
      • USA
      • Video
      • World
        • Asia
        • Africa
        • South America
        • North America
        • Europe
        • Oceania

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      The Insight Post
      Powered by  GDPR Cookie Compliance
      Privacy Overview

      This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

      Strictly Necessary Cookies

      Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

      Cookie Policy

      More information about our Cookie Policy